
Danaher Corporation’s (NYSE:DHR) portfolio, with 75% recurring revenues and more than a 90% mix in life sciences and diagnostics, appears “incrementally more attractive” amid the currently harsh macro environment, according to RBC Capital Markets.
The Danaher Analyst: Deane Dray upgraded Danaher from Sector Perform to Outperform, while raising the price target from $299 to $310.